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Interferon-Alpha-Induced Destructive Thyroiditis Followed by 
Graves’ Disease in a Patient with Chronic Hepatitis C: A Case 
Report
Interferon-induced thyroiditis (IIT) is a major clinical problem for patients receiving 
interferon-alpha (IFN-α) therapy. But, destructive thyroiditis followed by Graves’ disease 
associated with IFN-α therapy is very rarely reported. Herein, we report a rare case of 
pegylated IFN-α (pegIFN-α) induced destructive thyroiditis followed by Graves’ disease in   
a patient with HCV infection. A 31-yr-old woman suffered from chronic active hepatitis C 
and was treated with pegIFN-α and ribavirin for 12 months. Results of a thyroid function 
test and autoantibody levels were normal before IFN-α therapy was initiated. Destructive 
thyrotoxicosis appeared seven months after the initiation of IFN-α therapy, followed by 
Graves’ thyrotoxicosis two months after the cessation of therapy. The diagnoses of 
destructive thyroiditis and Graves’ disease were confirmed by the presence of TSH receptor 
antibodies in addition to Tc-99m scintigraphy findings. The patient’s antithyroglobulin 
antibody titer increased gradually during IFN-α therapy and remained weakly positive after 
IFN-α therapy was discontinued. 
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CASE REPORT
Endocrinology, Nutrition & Metabolism
INTRODUCTION
Interferon-alpha (IFN-α), which is the main therapeutic agent 
used for chronic hepatitis C virus (HCV) infection, is associated 
with side effects such as flu-like symptoms, hematologic abnor-
malities and thyroid disease. Prospective studies have shown 
that up to 40% of patients with HCV infection develop thyroid 
antibodies during IFN-α therapy (1), and around 15% develop 
thyroid disease (2). According to Tomer et al. (3), interferon-in-
duced thyroiditis (IIT) can be classified as either autoimmune or 
non-autoimmune. Autoimmune IIT includes the de novo pro-
duction of thyroid autoantibody without clinical disease, Hashi-
moto’s thyroiditis, and Graves’ disease, while non-autoimmune 
IIT presents as destructive thyroiditis or non-autoimmune hy-
pothyroidism (3). 
  The development of thyrotoxicosis during IFN-α treatment 
may be due to silent destructive thyroiditis or Graves’ disease. 
The development of Graves’ disease is a less common side effect 
of IFN-α therapy than is destructive thyroiditis. Moreover, de-
structive thyroiditis followed by Graves’ disease associated with 
IFN-α therapy occurs very rarely. Only four cases of destructive 
thyroiditis followed by Graves’ disease asso ciated with IFN-α 
treatment have been reported in the literature (4, 5). Herein, we 
report a recent case of pegylated IFN-α (pegIFN-α)-induced de-
structive thyroiditis followed by transient Graves’ disease in a 
patient with HCV infection. 
CASE DESCRIPTION
A 31-yr-old woman with hepatitis C-associated chronic active 
hepatitis proven on liver biopsy received pegIFN-α (Schering-
Plough, Korea) 2b 100 μg weekly and ribavirin 800 mg daily from 
June 2009 to May 2010. Prior to pegIFN-α therapy, laboratory 
testing revealed normal concentrations of total T3 at 2.25 nM/L 
(normal range: 1.1 to 2.9 nM/L), TSH at 1.011 mU/L (normal 
range: 0.35 to 5.50 mU/L), and free T4 at 15.18 pM/L (normal: 9 
to 26 pM/L), in addition to negative titers of antimicrosomal an-
tibody (MSAb) at 18 U/mL (negative < 60 U/mL) and antithyro-
globulin antibody (TGAb) at 26.7 U/mL (negative < 60 U/mL). 
Within two months of pegIFN-α therapy initiation she experi-
enced fever, chills, headaches and dizziness. Seven months into 
therapy (January 2010), the patient developed mild tremors and 
palpitation however she had no fever or pain. There was no ten-
derness and palpable nodule at physical examination. She has 
no personal and family history of thyroid dysfunction and no 
specific medication history. She also had not received any test 
that could interfere with the thyroid scan uptake. Results of re-
peated laboratory tests indicated elevated total T3 at 4.26 nM/L, Kim BK, et al.  •  Interferon-Induced Thyroiditis
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suppressed TSH at 0.009 mU/L, normal total T4 at 148.005 nM/
L (normal: 64 to 154 nM/L), and negative titers of MSAb at 27.1 
U/mL and TGAb at 31.1 U/mL. Thyrotropin-binding inhibitory 
immunoglobulin (TBII) was also negative at 2.6 U/L (normal 
range: 0 to 10 U/L). Tc-99m scintigraphy showed nonvisualiza-
tion of both thyroid lobes (Fig. 1A). Based on these findings, we 
diagnosed the patient with interferon-induced destructive thy-
roiditis and prescribed propranolol 20 mg/d for one month. 
  Two months later (March 2010), a follow-up thyroid function 
test demonstrated further decline in total T3 at 3.353 nM/L, 
TSH at 0.013 mU/L and total T4 at 128.7 nM/L. She continued 
pegIFN-α therapy for an additional four months, for a total treat-
ment duration of 12 months. Two months after the end of ther-
apy (July 2010), she complained of hand tremors, fatigability, 
and 3 kg of weight loss. Laboratory tests revealed a total T3 of 
12.288 nM/L, TSH of 0.004 mU/L, free T4 of 79.92 pM/L, and a 
TBII titer of 13.0 U/L. Tc-99m scintigraphy showed diffusely in-
creased uptake throughout the thyroid (Fig. 1B). In thyroid ul-
trasonography both thyroid glands were diffusely enlarged with 
increased vascularities and had heterogeneous echogenicities 
(Fig. 2). The diagnosis of Graves’ disease was made, and the pa-
tient started treatment with methimazole and propranolol. After 
nine months of antithyroid drug therapy (April 2011), her thy-
roid function tests showed normalized total T3 at 2.095 nM/L, 
TSH at 0.009 mU/L, free T4 at 21.36 pM/L, MSAb at 40.9 U/mL 
and TBII at 3.4 U/L. However, her TGAb titer was weakly posi-
tive at 63.9 U/mL.
A B
Fig. 1. Tc-99m scintigraphy showing non-visualization of the thyroid gland (A) and increased uptake throughout (B).
A B
Fig. 2. Thyroid ultrasonography showing diffuse enlargement and coarse parenchyma of both thyroid gland (A) and increased vascularities (B).Kim BK, et al.  •  Interferon-Induced Thyroiditis
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DISCUSSION 
IFN-α is an immunoregulatory cytokine that is currently used 
as a therapeutic agent for chronic HCV infection. Almost all pa-
tients who receive IFN-α therapy experience side effects. The 
most common adverse effects of IFN-α are muscle aches and 
fatigue, but more difficult to manage are the psychological side 
effects such as depression, anxiety, irritability, sleep disturbance, 
and difficulty concentrating (6). Our patient also experienced 
fever, chills, headaches and dizziness during treatment. 
  The association between interferon and thyroid disease was 
reported as early as 1985 (7). Since then, numerous studies have 
reported a high incidence of thyroid abnormalities in patients 
treated with interferon (8, 9). For many years it was assumed that 
side effects associated with IFN-α therapy were due to immune 
dysregulation. However, while immune mechanisms must play 
a role in the development of IIT, the predilection to the thyroid 
and the non-autoimmune manifestations of IIT suggest that di-
rect effects of IFN-α on the thyroid play a major role in the etiol-
ogy of IIT (10). 
  The most common clinical manifestation of IIT is Hashimo-
to’s thyroiditis. Hashimoto’s thyroiditis is most likely to occur 
during the course of treatment and has been reported in 45%-
60% of patients with pre-existing thyroid autoantibodies (TAbs) 
compared to 3%-5% of those with no circulating thyroid anti-
bodies prior to interferon treatment (11). Therefore, TAbs levels 
should be assessed prior to the initiation of IFN therapy. Our 
case had a negative TAbs titer prior to IFN therapy. 
  TAbs can develop de novo during IFN therapy or their levels 
can increase during IFN therapy. The majority of individuals 
who develop de novo TAbs due to IFN-α therapy remain TAbs-
positive after treatment is completed. The incidence of de novo 
TAbs in interferon-treated HCV patients ranges from 10% to 40% 
(1, 2, 12), and TAbs develop more frequently in women treated 
with IFN-α than in men. Our case demonstrated de novo pro-
duction of TGAb after IFN-α therapy completion. Her TGAb titer 
progressively increased from 26.7 U/mL to 31.1 U/mL during 
IFN-α therapy and remained weakly positive at 63.9 U/mL after 
the treatment period. The TGAb titer associated with IFN-α ther-
apy seems to increase over time.
  Classical destructive thyroiditis initially presents as transient 
thyrotoxicosis with decreased radionuclide uptake, which de-
velops in three phases, followed inconsistently by a hypothy-
roid phase that eventually resolves spontaneously within several 
weeks to months. More than 50% of IIT patients with thyrotoxi-
cosis have destructive thyroiditis. Graves’ disease is character-
ized by overt hyperthyroidism with the presence of thyroid stim-
ulating hormone receptor antibody (TSHRAb) and/or diffusely 
increased radioactive iodine uptake. IFN-α-induced Graves’ dis-
ease is less common than is destructive thyroiditis, affecting 1%-
2% of patients during IFN-α therapy and can manifest following 
INF-α therapy completion (13, 14). Typically, IFN-α-induced 
Graves’ disease patients present with symptomatic thyrotoxico-
sis and do not go into remission upon completion or cessation 
of IFN-α therapy. In our patient, Graves’ disease developed two 
months after IFN-α therapy completion. Her free T4 concentra-
tion was normalized after one month of antithyroid drug treat-
ment; however, her TSH level remained suppressed after nine 
months of antithyroid drug therapy.
  Destructive thyroiditis developed in our case after seven 
months of IFN-α therapy, and Graves’ disease was diagnosed 
after treatment completion. Our case is similar to only one pre-
viously reported case. In 1995, Koizemi et al. (4) described a 
woman who, after three months of IFN-α therapy, successively 
developed transitory thyrotoxicosis, followed three months lat-
er by recurrent hyperthyroidism and the development of high 
TSHRAb titers. In this case, thyroid peroxidase antibody (TPOAb), 
TGAb, and TSHRAb titers were elevated at the time of IFN-α 
therapy cessation, and symptoms of Graves’ disease developed 
four months later. Neither our case nor that reported by Koize-
mi and colleagues exhibited a hypothyroid phase. However, 
Bohbot et al. (5) reported three patients with classical destruc-
tive thyroiditis followed by Graves’ disease manifesting during 
IFN-α therapy. In those cases, the time to the appearance of the 
destructive hyperthyroidism phase was 4-6 months, with the 
Graves’ disease phase arising at 8-11 months. These intervals 
are slightly shorter than that observed in our case. 
  It is unclear how IFN-α induces Graves’ disease, but the un-
derlying mechanism is thought to be causally related to autoim-
munity. The majority of patients have thyroid stimulating anti-
body. Some cases of transient thyrotoxicosis followed by Graves’ 
hyperthyroidism not associated with IFN-α therapy have been 
reported (15-17). In those cases, destruction of thyroid tissues 
and release of autoantigens could have resulted in altered im-
munotolerance, and the subsequent production of thyroid stim-
ulating antibody may have caused hyperthyroidism. 
  IFN-α can induce both autoimmune and non-autoimmune 
thyroiditis. However, we observed a rare side effect of IFN-α ther-
apy as IFN-α-induced destructive thyroiditis followed by tran-
sient Graves’ disease in a patient with HCV infection.
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